New Retrospective Study Shows PS-Omega-3 Medical Food Effective in Managing ADHD
April 28 2016 - 10:46AM
Nearly a Third of Children Who Experienced a Benefit While
Taking PS-Omega-3 Were Also Able to Reduce Their ADHD Medication
Dose
According to a new retrospective study conducted at Texas Child
Neurology and Children's Health Services, children diagnosed with
attention deficit hyperactivity disorder (ADHD) who took PS-Omega-3
(phosphatidylserine omega-3) medical food experienced a reduction
of symptoms and, of these patients, nearly a third of them were
able to reduce their ADHD medication while on the medical food. The
study’s lead researchers indicated that PS-Omega-3 appears to be a
safe and effective non-drug approach for the dietary management of
ADHD.
The study was showcased during a poster presentation at the
National ADHD Conference from April 7-8, 2016 in Tel Aviv, Israel.
The retrospective study, an independent study initiated by Robert
Chudnow, M.D. at Texas Child Neurology and Tate Holbrook, M.D. at
Children’s Health Services, used VAYA™ Pharma’s Vayarin® PS-Omega-3
as the medical food. The composition found in Vayarin, PS-Omega-3,
is a proprietary formulation of phosphatidylserine connected to
Omega-3 fatty acids that is an essential structural and biochemical
component of cell membranes.
“According to the Centers for Disease Control and Prevention,
more than 6 million children in the U.S. suffer from ADHD and the
symptoms that accompany the disease, including emotional
dysregulation, aggression, impulsivity, hyperactivity, difficulty
focusing, among other challenges,” said lead investigator Tate
Holbrook, M.D. at Children’s Health Services. “Our analysis showed
that patients taking Vayarin reported a reduction in ADHD symptoms
and, what’s more, many patients were able to reduce the dose of
their current ADHD medication, which may help alleviate unpleasant
side effects.”
Study OverviewIn the analysis, the effect of
Vayarin was retrospectively evaluated in 518 patients, average age
of 11 years, with ADHD. Researchers at Texas Child Neurology in
Plano, TX and Children's Health Services in Greenville, NC used
electronic health records (EHR) to identify ADHD patients that were
administrated Vayarin for different durations.
The effect of Vayarin was assessed based on patient and parent
self-assessments. Reduced ADHD symptoms were reported by 68 percent
of patients taking Vayarin. Similar response rates (66 percent)
were observed for adjunct use of Vayarin with ADHD stimulant and
non-stimulant prescription medication. In addition, 31 percent of
patients who experienced a benefit while on Vayarin were also able
to reduce their dose of ADHD medication.
“Since our clinics specialize in pediatric neurology, we’re
continually looking for new ways to safely alleviate the symptoms
of ADHD for children and to support their overall quality of life,”
commented lead investigator Robert Chudnow, M.D. at Texas Child
Neurology. “We are pleased to see – through this retrospective
study – that Vayarin helps to bridge the gap of nutritional
deficiencies commonly associated with ADHD, giving children and
their families a non-drug approach to managing ADHD symptoms.”
VAYA PharmaVAYA Pharma, a division of Enzymotec
Ltd (NASDAQ:ENZY), is the innovator of lipid-based medical foods
that are used to manage distinct nutritional deficiencies
associated with certain diseases and health conditions, including
attention deficit hyperactivity disorder (ADHD), early memory
impairment (EMI) and hypertriglyceridemia. Committed to safety and
efficacy, VAYA Pharma’s innovations – Vayarin®, Vayacog® and
Vayarol® – are backed by years of clinical research. Its products
are available in the U.S. by prescription under the supervision of
a physician. VAYA Pharma is headquartered in Baltimore, Maryland.
For more information, visit www.vayapharma.com.
Forward-Looking StatementsThis press release
may contain forward-looking statements related to VAYA Pharma’s
business strategy, outlook, objectives, plans, intentions or goals.
The words "may," "will," "should," "plans," "explores," "expects,"
"anticipates," "continue," "estimate," "project," "intend," and
similar expressions, identify forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995,
but their absence does not mean that the statement is not
forward-looking. These statements are not guarantees of future
performance and are subject to certain risks, uncertainties, and
assumptions that are difficult to predict. Actual results could
differ materially. VAYA Pharma expressly disclaim any obligation or
undertaking to update or revise any forward-looking statement
contained herein to reflect any change in the company's
expectations with regard thereto or any change in events,
conditions or circumstances upon which any statement is based.
For more information:
VAYA Pharma
Shervin Esfahani
443.995.4299
ShervinE@vayapharma.com
Andrea Martin (on behalf of VAYA Pharma)
Andrea D. Martin Consulting, LLC
443.927.6183
andrea@consultmartin.com
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jun 2024 to Jul 2024
ENZYMOTEC LTD. (NASDAQ:ENZY)
Historical Stock Chart
From Jul 2023 to Jul 2024